Hypertension, cognitive decline and dementia
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Dementia is one of the most common neurological disorders in the elderly. Aging is associated with a large increase in the prevalence and incidence of degenerative (Alzheimer's disease) and vascular dementia, leading to a devastating loss of independence. In view of increasing longevity of populations worldwide, prevention and treatment of dementia has turned into a major public health challenge. In the past decade, longitudinal studies have shown a close association between high blood pressure in middle age, cognitive decline and dementia, including Alzheimer's disease, in the late life. Pathophysiologically, a summation of cerebrovascular damage, white matter changes and pre-existing asymptomatic Alzheimer's brain lesions may lead to dementia, even when each type of lesion individually is not sufficiently severe to cause it. Longitudinal studies assessing the beneficial role of antihypertensive drugs on cognitive decline and dementia have produced promising results. There are few randomised placebo controlled studies, although some of these have produced positive results. Results of three recent meta-analyses are inconsistent, possibly due to methodological issues. Further long-term randomised trials, designed especially to assess a link between antihypertensive therapy and cognitive decline or dementia are therefore needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 1×
“The study by Skoog et al. [11], conducted in 1996, is particularly useful to explain the occasionally contradictory results of the different other studies.”
ResultKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 1×
“Another study which included 1,449 people showed that raised systolic blood pressure (SBP) to over 140 mmHg in midlife was associated with a significantly increased risk of AD 21 years later [7].”
BackgroundForette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 1×
“The vascular dementia project included in SYST-EUR trial [29] was the first to find a reduction in the incidence of dementia associated with anti-hypertensive treatments.”
BackgroundLindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 1×
“Three of these studies found no significant association between taking an anti-hypertensive agent and AD [18], [19], [20].”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 1×
“A 24% significant increase in risk of dementia 30 years later was found in hypertensive patients at inclusion in a recent retrospective study of 8,845 subjects initially between 40 and 44 years old [10].”
BackgroundMidlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1069 · Cited by 988
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Cardiovascular risk factors and cognitive decline in middle-aged adults
Knopman, D., Boland, L. L., Mosley, T., Howard, G., Liao, D., Szklo, M., McGovern, P., & Folsom, A. R. (2001) · Neurology · doi:10.1212/wnl.56.1.42 · Cited by 883
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
Hypertension Is Related to Cognitive Impairment: A 20-Year Follow-up of 999 Men
Kilander, L., Nyman, H., Boberg, M., Hansson, L., & Lithell, H. (1998) · Hypertension · doi:10.1161/01.hyp.31.3.780 · Cited by 630
Vascular risk factors, incidence of MCI, and rates of progression to dementia
Solfrizzi, V., Panza, F., Colacicco, A. M., D’Introno, A., Capurso, C., Torres, F., Grigoletto, F., Maggi, S., Del Parigi, A., Reiman, E. M., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000144281.38555.e3 · Cited by 530
Waldstein, S. R., Rice, S. C., Thayer, J. F., Najjar, S. S., Scuteri, A., & Zonderman, A. B. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.093674 · Cited by 462
Dufouil, C., Chalmers, J., Coskun, O., Besançon, V., Bousser, M.-G., Guillon, P., MacMahon, S., Mazoyer, B., Neal, B., Woodward, M., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.501163 · Cited by 461
Tervo, S., Kivipelto, M., Hänninen, T., Vanhanen, M., Hallikainen, M., Mannermaa, A., & Soininen, H. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000076356 · Cited by 298
Hanon, O., Haulon, S., Lenoir, H., Seux, M.-L., Rigaud, A.-S., Safar, M., Girerd, X., & Forette, F. (2005) · Stroke · doi:10.1161/01.str.0000181771.82518.1c · Cited by 280 · cited 1×
“In the same context the study found a positive association between arterial stiffness measured by the pulse wave velocity and cognitive disorders [9].”
BackgroundSelf-citationYamada, M., Kasagi, F., Sasaki, H., Masunari, N., Mimori, Y., & Suzuki, G. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51117.x · Cited by 255 · cited 2×
“2003 [60] 1774 ≥65 25 BP (continuous variable) No significant association”
Antihypertensive drugs and incidence of dementia: the Rotterdam Study
in’t Veld, B. A., Ruitenberg, A., Hofman, A., Stricker, B. H. C., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00241-4 · Cited by 254 · cited 1×
“The Rotterdam study found that antihypertensive treatments had a role in preventing VaD although this association was not significant for AD [21].”
BackgroundMixed Dementia: Epidemiology, Diagnosis, and Treatment
Zekry, D., Hauw, J., & Gold, G. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50367.x · Cited by 243 · cited 1×
“In 25 to 50% of cases, histological examination of dementia patients reveals the co-existence of cerebrovascular lesions and histological lesions of Alzheimer’s disease [38].”
BackgroundMorris, M. C., Scherr, P. A., Hebert, L. E., Glynn, R. J., Bennett, D. A., & Evans, D. A. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1640 · Cited by 217 · cited 1×
“Three of these studies found no significant association between taking an anti-hypertensive agent and AD [18], [19], [20].”
BackgroundDi Bari, M., Pahor, M., Franse, L. V., Shorr, R. I., Wan, J. Y., Ferrucci, L., Somes, G. W., & Applegate, W. B. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.1.72 · Cited by 193
Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension
Peila, R., White, L. R., Masaki, K., Petrovitch, H., & Launer, L. J. (2006) · Stroke · doi:10.1161/01.str.0000217653.01615.93 · Cited by 181 · cited 1×
“The “Honolulu Asia Aging” study highlighted the importance of the duration of anti-hypertensive treatment: the reduction in the risk of dementia increased with each additional year of antihypertensive treatment [25].”
BackgroundCalcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116
Birns, J., Morris, R., Donaldson, N., & Kalra, L. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000244934.81180.16 · Cited by 96
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 1×
“[22] or AD (36 to 50% reduction) [23-24] that was associated with anti-hypertensive treatment.”
Background
Cited by
Berendsen, A. A. M., Kang, J. H., van de Rest, O., Jankovic, N., Kampman, E., Kiefte-de Jong, J. C., Franco, O. H., Ikram, M. A., Pikhart, H., Nilsson, L. M., et al. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000464269 · Cited by 562
Buford, T. W. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.007 · Cited by 561
Daulatzai, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 429
Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Smith, P. J., Blumenthal, J. A., Babyak, M. A., Craighead, L., Welsh-Bohmer, K. A., Browndyke, J. N., Strauman, T. A., & Sherwood, A. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.146795 · Cited by 341
Metadata
- Authors
- Duron, E., & Hanon, O.
- Venue
- Archives of Cardiovascular Diseases
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 101
- Issue
- 3
- Pages
- 181-189
- ISSN
- 1875-2128 (ISSN-L)
- 1875-2136
- OpenAlex
- W2029309391
- Cited by
- 123
- References
- 26
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.